



RESEARCH ARTICLE

CANDIDURIA: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE

¹Dr. Seema Bisane and ^{2,*}Dr. Silpi Basak

¹Post Graduate student, Dept. of Microbiology, Jawaharlal Nehru Medical College, Wardha (MS), Pin-442107

²Professor, Dept. of Microbiology, Jawaharlal Nehru Medical College, Wardha (MS), Pin-442107

ARTICLE INFO

Article History:

Received 29th June, 2018
Received in revised form
25th July, 2018
Accepted 10th August, 2018
Published online 30th September, 2018

Key Words:

Candiduria, Candida Albicans,
Candida non-Albicans,
Fluconazole resistance.

ABSTRACT

Introduction: In recent years, *Candida* sp. has appeared as an emerging nosocomial pathogen causing Urinary Tract Infections. Candiduria is difficult to diagnose clinically as most often the patient is asymptomatic. Patients with candiduria often develop candidemia. Standard urine culture is less sensitive. Resistance to antifungal drugs have been more commonly encountered in *Candida* species isolated from urine. **Aim:** Hence, the present study was undertaken to detect the incidence of different *Candida* species isolated from urine and to study their antifungal drug susceptibility profile. **Material and Methods:** 630 urine samples were cultured on Sabouraud's Dextrose agar (SDA) with chloramphenicol. 55 *Candida* strains were detected by conventional tests. 05 *Candida albicans* and 07 *Candida nonalbicans* strains were further confirmed by Vitek2. Antifungal drug susceptibility profile was detected by disc diffusion method as per CLSI Guidelines. Minimum Inhibitory Concentration (MIC) of Fluconazole and Voriconazole was detected by E Test (bio Merieux). **Results:** *Candida tropicalis* was the commonest species (36.4%) followed by *Candida albicans* (29.1%), *Candida parapsilosis* (16.4%), *Candida glabrata* (7.3%) and *Candida pelliculosa* (7.3%). 22 (40%) *Candida* species were resistant to Fluconazole. Fluconazole MIC > 96 µg/ml was observed in 10 strains. **Conclusion:** Routinely all urine sample should be cultured on SDA for detection of Candiduria and antifungal drug sensitivity test should be done.

Copyright © 2018, Seema Bisane and Silpi Basak., This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Dr. Seema Bisane and Dr. Silpi Basak. 2018. "Candiduria: A diagnostic and therapeutic challenge", *International Journal of Current Research*, 10, (09), 73214-73217.

INTRODUCTION

In recent years, *Candida* sp. has appeared as an emerging nosocomial pathogen causing Urinary Tract Infections (UTI). Risk factors for candiduria include indwelling catheters, prolonged ICU stay, female sex, anatomical abnormality of urinary tract, prolonged antibiotic therapy, Diabetes mellitus and other co-morbid conditions etc. Candiduria is difficult to diagnose clinically as most often the patients are asymptomatic. Even pus cells are not present in most of the cases (Achkar, 2010). Around 1-8% candiduric patients develop candidemia especially ICU patients. Standard routine urine culture is less sensitive and may lead to under estimation of Candiduria. Resistance to antifungal drugs have been more commonly encountered in *Candida albicans* and non-albicans species isolated from urine. Resistance may be intrinsic or acquired type. Hence, the present study was undertaken to detect the incidence of different *Candida* species isolated from urine and to study their antifungal drug susceptibility profile.

*Corresponding author: Dr. Silpi Basak,

Professor, Dept. of Microbiology, Jawaharlal Nehru Medical College, Wardha (MS), Pin-442107.

DOI: <https://doi.org/10.24941/ijcr.32194.09.2018>

MATERIALS AND METHODS

This short term cross-sectional experimental study was conducted in the department of Microbiology and was approved by Institutional Ethics Committee. Total 630 urine specimens, collected from Indoor Patient Departments (IPD) were cultured on Sabouraud's Dextrose agar (SDA) in the Department of Microbiology. Our Hospital is a tertiary care hospital in a rural set up. All urine samples were inoculated on Sabouraud's Dextrose agar (SDA) with chloramphenicol. The plates were incubated at 37 °C up to 48 hrs. Only the urine samples having pure growth of *Candida* species were included in the study. The colony morphology of each isolate was observed by Gram's staining, and if Gram positive budding yeast cells were observed then it was further processed. 55 *Candida* strains were detected by conventional tests like microscopy, culture, Gram staining, Germ tube formation, colour on CHROM agar, chlamydospore formation on cornmeal agar, sugar assimilation test (Koneman *et al*, 2006). The nonalbicans species which were not identified by conventional tests were confirmed by Vitek2 YST ID card. Hence, 5 *Candida albicans* and 7 Non-albicans species were further confirmed by Vitek 2 YST ID card.

Antifungal drug susceptibility was detected by disc diffusion method by using Mueller Hinton agar supplemented with 2% glucose and 0.5µg/ ml of methylene blue according to Clinical Laboratory Standard Institute (CLSI) Guidelines CLSI M44-A2 (CLSI, 2010). The reading was taken by measuring the growth inhibition zone. Results were expressed as susceptible (S), susceptible dose-dependant (SDD), and resistant (R) [3].

Minimum Inhibitory Concentration (MIC) of Fluconazole and Voriconazole were detected by E-test (bioMeriux) on SDA plate as per manufacturer’s instruction. The Control strains used were *C. albicans* ATCC 90028 and *C. tropicalis* ATCC 750.

OBSERVATIONS AND RESULTS

A total 55 candida strains were isolated from 630 urine samples. Among them Non-albicans Candida species 39 (70.9%) were predominant compared to *Candida albicans* 16 (29.1%). The Non-albicans Candida species included *C. tropicalis* 20 (36.4%), *C. parapsilosis* 9 (16.4%), *C. glabrata* 4 (7.3%), *C. pelliculosa* 4 (7.23%), *C. krusei* 1 (1.3%) and *C. kefyr* 1 (1.3%).The most common species isolated was Candida tropicalis.




Fig. 1. Incidence of different Candida sp. isolated (n=55)




Fig. 2: Isolation of Candida strains from different hospital wards (n=30)




Fig. 3. Isolation of Candida strains from different ICUs (n=25)

Table 1. Isolation of Candida strains from male and female patients (n=55)

Male	Female	Ratio
24	31	1:1.3

Table 2. Isolation of Candida strains from catheterised and non catheterised patients (n=55)

Catheterized	Non-catheterized
46	09
83.7%	16.3%

Table 3. Antifungal sensitivity pattern to Voriconazole (VRC) & Fluconazole (FLC) by disc diffusion method

Sensitive to both VRC & FLC	24
Resistant to both VRC & FLC	16
Resistant to only VRC	0
Resistant to only FLC	4
SDD to FLC	6
Sensitive to only VRC	15






Fig. 4. Isolation of Candida species from patients with Health care Associated Infections (HAI)




Photograph 1 Shows Candida strain

- a-Resistant to both Fluconazole & Voriconazole,
- b- Sensitive to both Fluconazole & Voriconazole,
- c- Sensitive to only Voriconazole

Out of total 55 Candida isolates, 30 strains were isolated from hospital wards and 25 strains from ICUs. Maximum number of Candida strains i.e. 8 were isolated from Obstetrics and Gynaecology ward.



Fluconazole MIC: 1.5 µg/ml



Voriconazole MIC: .012 µg/ml

Photograph 2. MIC of Fluconazole and Voriconazole by E Test (bioMérieux)

Among 30 *Candida* strains isolated from different wards 10 (18.2%) were *C. tropicalis*, followed by 8 (14.5%) *C. albicans*, 6 (10.9%) *C. parapsilosis*, 4 (7.3%) *C. pelliculosa* and 2 (3.6%) *C. glabrata*. 25 *Candida* strains were isolated from different ICUs. Maximum number of *Candida* strains i.e. 14 (56%) were isolated from Medicine ICU. Out of these 25 strains, 10 (40%) were *C. tropicalis* followed by 8 (32%) *C. albicans*, 3 (12%) were *C. parapsilosis*, 2 (8%) were *C. glabrata* and 1 (4%) each were *C. kefyr* and *C. krusei* respectively. Table 1 shows the number of male patient were 24 and female patient were 31. Male to female ratio was 1:1.3, showing female preponderance. Table 2 shows 46 (83.7 %) patients were catheterized for more than 5-7 days, which was statistically significant where p value was <0.005; and 9 (16.3 %) patients were non-catheterized. A total number of 48 (87.3%) patients were with Health care Associated infections (HAI). 55.5% patients were from different hospital wards and 45.5% patients were from different ICUs. 46 (83.7%)

Candida strains were isolated from catheterised patients and 2 strains from non catheterised patients. 4 strains of *C. glabrata* and 1 strain of *C. krusei* were excluded from fluconazole susceptibility test as they are intrinsically resistant to fluconazole. Hence, only 50 strains were tested for fluconazole susceptibility, whereas all 55 *Candida* strains were tested for voriconazole susceptibility. Antifungal susceptibility pattern showed 24 strains sensitive to both fluconazole and voriconazole, 16 strains resistant to both fluconazole and voriconazole. There was no strain resistant to only voriconazole. 4 strains were resistant to only fluconazole and 6 strains were susceptible-dose-dependent (SDD) to fluconazole. Total 20 (40%) strains were resistant to fluconazole.

DISCUSSION

In the present study, the incidence of candiduria by non-*albicans* species (70.9%) was high compared to *C. albicans* (29.1%) and this changing trends in etiopathogenesis of UTI is a matter of concern. The result was comparable to another study where *non albicans Candida* species were predominant (66.7%), compared to *Candida albicans* (33.3%) (Goyal *et al.*, 2016). *Candida tropicalis* was the commonest species (36.4%) in our study followed by *Candida albicans* (29.1%) which was also reported by other workers that the most common species was *C. tropicalis* (68.2 %) followed by *C. albicans* (32 %) (Choudhary *et al.*). In this study, female preponderance was observed with overall male: female ratio as 1:1.3 indicating that female gender is a risk factor which was also comparable with the study which has reported the ratio as 1:1.3 (Goyal *et al.*, 2016). 25 *Candida* isolates were from Intensive care units including 14 from medicine ICU which also correlated well with other study (Sharma *et al.*, 2016). The most important predisposing factor for Candiduria in hospitalized patients is catheterization. In the present study, 83.7 % patients were catheterized for more than 7 days which was found to be statistically significant ($p = <0.005$) when compared with noncatheterised patients having Candiduria. It has been reported that the risk of non-*albicans* candiduria increases 0.2-0.5 times higher with urinary catheterization and on admission to ICU or surgical units (Sharma *et al.*, 2016). Species identification is important before starting the antifungal therapy as few species of *Candida* are intrinsically resistant to some antifungals. In present study, Antifungal susceptibility showed 40% resistance to Fluconazole which is comparable to other study i.e. 48.4% (Mohamoudabadi *et al.*, 2013). In a tertiary care centre of South India, 30.8% resistance to fluconazole was noted (Giri *et al.*, 2013).

Conclusion

We hereby conclude that there is need of considering candiduria as an emerging nosocomial infection, which represents diagnostic and therapeutic challenge for clinician. Routinely all urine samples should be cultured on SDA for detection of Candiduria and species identification and antifungal drug sensitivity test should be done for effective treatment of the patient.

Acknowledgement

The authors acknowledge the financial support rendered by Datta Meghe Institute of Medical Sciences (Deemed to be University), India.

REFERENCES

- Achkar J.M., Fries B.C. 2010. Candida Infections of Genitourinary tract. *Clin. Microbio. Reviews.* 23(2); 253-273.
- Choudhury, R.C., Nautiya S., Maheswari B. 2015. Candiduria: current scenario, *IOSR Journal Of Pharmacy* (e)-ISSN: 2250-3013, (p)-ISSN: 2319-4219.
- Clinical and laboratory standards institute. Method for antifungal disk diffusion susceptibility testing of yeasts: approved guideline M44-A2. CLSI, Wayne, PA, USA, 2010.
- Giri S., Kindo AJ., Kalyani J. 2013. Candidemia in intensive care unit patients: a one year study from a tertiary care center in SouthIndia. *J Postgrad Med.*, 59(3): 190-195.
- Goyal R. K. and Hiba Sami *et al.* 2016. Non-albicansCandiduria: An emerging threat, *Journal of Applied Pharmaceutical Science* Vol. 6 (03), pp. 048-050.
- Koneman FW., Allen SD., Janda WM., Wine WC., Procorp GW *et al.* 2006. Koneman's colour atlas and textbook of Diagnostic Microbiology.6thedn. Philadelphia: Lippincott Williams and Wilkins, pp. 1216-1238.
- Mahamoudabadi Z.A., Zarrim M, Beheshti Fard M. 2013. Antifungal susceptibility of Candida species isolated from Candiduria. *Jundishapur J. Microbiology.* 6(1):24-8. DOI:10.5812/JJM.4633.
- Sharma A., Dogra V., Mishra B. *et al.* 2016. *Candida albicans* versus non albicanscandiduria in the ICU setting: evaluation of risk factors. *J Bacteriol Mycol Open Access.*3 (4):297–300. DOI: 10.15406/jbmoa.2016.03.00074.
